Overview

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
The propose of this study is to confirm safety and efficacy of Apatinib monotherapy in patients with advanced cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib